Back to Agenda
CANCELLED: HTA AND PRICING POLICIES IN EU AFTER THE TRANSPARENCY DIRECTIVE
Session Chair(s)
Richard Bergström, MS
Director General
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
The EU Transparency Directive has been in force since more than 20 years. The European Commission has proposed to update the directive and to also subject HTA to the procedural rules (including timelines) of the directive. The proposal is currently under discussion in Council and the European Parliament. Regardless of the outcome of these discussions, HTA is at the core of EU policy-making on pharmaceuticals. This session will explore the latest developments of the directive and discuss how the legal framework for HTA is evolving.
Speaker(s)
HTA in Europe: Within or outside the Directive - does it make a difference?
Andrea Rappagliosi, LLM
Sanofi Pasteur MSD, France
Vice-President Market Access, Health Policy and Medical Affairs
Have an account?